tert-butyl 3-hydroxy-4,7-dihydroisoxazolo[5,4-c]pyridine-6(5H)-carboxylate | 83491-28-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: tert-butyl 3-hydroxy-4,7-dihydroisoxazolo[5,4-c]pyridine-6(5H)-carboxylate
• 英文别名: tert-butyl 3-hydroxy-4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridine-6-carboxylate；3-Hydroxy-6-(t-butyloxycarbonyl)-4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridine；tert-butyl 3-oxo-5,7-dihydro-4H-[1,2]oxazolo[5,4-c]pyridine-6-carboxylate
• CAS: 83491-28-5
• 化学式: C₁₁H₁₆N₂O₄
• 分子量: 240.259
• InChiKey: UQUVDVDVWUYBDL-UHFFFAOYSA-N

物化性质

• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-hydroxy-4,7-dihydroisoxazolo[5,4-c]pyridine-6(5H)-carboxylate 在 三乙胺 、 三氟乙酸 作用下， 以 苯 为溶剂， 反应 3.0h， 生成 oxalic acid;4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-3-yl pyrrolidine-1-carboxylate
  参考文献：
  名称：

  Haefliger; Revesz; Maurer, European Journal of Medicinal Chemistry, 1984, vol. 19, # 2, p. 149 - 156

  摘要：

  DOI：
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 、 乙酸乙酯 为溶剂， 生成 tert-butyl 3-hydroxy-4,7-dihydroisoxazolo[5,4-c]pyridine-6(5H)-carboxylate
  参考文献：
  名称：

  Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one,

  摘要：

  4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-酮的羰酰衍生物，其制备方法，药物组合物以及利用其治疗GABA系统功能障碍的方法均已披露。

  公开号：

  US04353910A1

文献信息

• Isoxazolo(5,4-c)pyridine derivatives, their preparation and pharmaceutical compositions containing them
  申请人：H.Lundbeck & Co., A/S

  公开号：EP0000338A2

  公开（公告）日：1979-01-24

  Isoxazolo-(5,4-C)-pyridine derivatives of the formula in which R" is hydrogen, acetyl or a group of the formula R5OCO- in which Rs is C1-4-alkyl, phenyl, substituted phenyl; phenylalkyl or substituted phenylalkyl and salts thereof, and intermediates IV, VIII', IX' and V. Compounds (I) may be prepared according to the following reaction scheme: in which Z is hydrogen or a protecting group, T is a group convertible by hydrolysis into an oxo group, Q is a leaving group and W is hydrogen or a group removable to yield the free hydroxy group. Compounds (I) exhibit a y-aminobutyric acid related activity and are useful as active ingredients in pharmaceutical compositions which may, optionally, further contain a minor tranquilizer or a neuroleptic.

  式中的异噁唑-(5,4-C)-吡啶衍生物 其中 R "为氢、乙酰基或式 R5OCO-的基团，其中 Rs 为 C1-4-烷基、苯基、取代苯基；苯基烷基或取代苯基烷基及其盐，以及中间体 IV、VIII'、IX'和 V。 化合物 (I) 可根据以下反应方案制备： 其中 Z 为氢或保护基，T 为可通过水解转化为氧代基团的基团，Q 为离去基团，W 为氢或可去除以产生游离羟基的基团。 化合物(I)具有与 y-氨基丁酸相关的活性，可作为药物组合物中的活性成分，这些药物组合物还可进一步含有轻微的镇静剂或神经安定剂。
• PHARMACEUTICAL COMPOSITION FOR TREATING ANGELMAN SYNDROME
  申请人：Ovid Therapeutics, Inc.

  公开号：EP3795156A1

  公开（公告）日：2021-03-24

  The invention relates to a pharmaceutical composition comprising an effective amount of 4,5,6,7- tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) or a pharmaceutically effective salt thereof and a pharmaceutically acceptable carrier or excipient for use in a method of treating a human subject with Angelman syndrome, wherein the pharmaceutical composition is administered to the subject at a dosage of 0.1-5.0 mg THIP / kg.

  本发明涉及一种药物组合物，该药物组合物包含有效量的 4,5,6,7- 四氢异恶唑并(5,4-c)吡啶-3-醇 (THIP) 或其药学上有效的盐和药学上可接受的载体或赋形剂，用于治疗人类安杰曼综合征患者的方法，其中该药物组合物以 0.1-5.0 毫克 THIP / 千克的剂量给药。
• [EN] RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS<br/>[FR] GABOXADOL À CYCLE DÉUTÉRIÉ ET SON UTILISATION POUR LE TRAITEMENT DE TROUBLES PSYCHIATRIQUES
  申请人：CERTEGO THERAPEUTICS INC

  公开号：WO2021236876A3

  公开（公告）日：2022-01-06
• Biostructural and Pharmacological Studies of Bicyclic Analogues of the 3-Isoxazolol Glutamate Receptor Agonist Ibotenic Acid
  作者：Karla Frydenvang、Darryl S. Pickering、Jeremy R. Greenwood、Niels Krogsgaard-Larsen、Lotte Brehm、Birgitte Nielsen、Stine B. Vogensen、Helle Hald、Jette S. Kastrup、Povl Krogsgaard-Larsen、Rasmus P. Clausen

  DOI：10.1021/jm101218a

  日期：2010.12.9

  We describe an improved synthesis and detailed pharmacological characterization of the conformationally restricted analogue of the naturally occurring nonselective glutamate receptor agonist ibotenic acid (RS)-3-hydroxy-4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridine-7-carboxylic acid (7-HPCA, 5) at AMPA receptor subtypes. Compound 5 was shown to be a subtype-discriminating agonist at AMPA receptors with higher binding affinity and functional potency at GluA1/2 compared to GluA3/4, unlike the isomeric analogue (RS)-3-hydroxy-4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridine-5-carboxylic acid (5-HPCA, 4) that binds to all AMPA receptor subtypes with comparable potency. Biostructural X-ray crystallographic studies of 4 and 5 reveal different binding modes of (R)-4 and (5)-5 in the GluA2 agonist binding domain. WaterMap analysis of the GluA2 and. GluA4 binding pockets with (R)-4 and (5)-5 suggests that the energy of hydration sites is ligand dependent, which may explain the observed selectivity.
• PERREGAARD, J. K.
  作者：PERREGAARD, J. K.

  DOI：——

  日期：——